news
Life Biosciences reports first human trial data for cellular rejuvenation therapy
Life Biosciences announced interim Phase 1 clinical data for ER-100, testing its cellular rejuvenation gene therapy in three participants with open-angle glaucoma. The platform uses three Yamanaka factors to restore aging retinal ganglion cells back to a younger state. Early results showed the treatment was well tolerated without serious adverse events.
Life Biosciences announced interim Phase 1 clinical data for ER-100, testing its cellular rejuvenation gene therapy in three participants with open-angle glaucoma. The platform uses three Yamanaka factors to restore aging retinal ganglion cells back to a younger state. Early results showed the treatment was well tolerated without serious adverse events.
The architecture take
I used to roll my eyes whenever longevity startups promised they would reverse cellular age in living tissue, but this tiny trial made me pause. Life Biosciences just reported early safety data on ER-100, an injectable gene therapy using three Yamanaka factors to reset damaged retinal cells in three glaucoma patients. The biology targets the nerve. In mice, expressing Oct4, Sox2, and Klf4 cleared accumulated DNA damage, boosted mitochondrial output, and restored visual function. Now three human participants have received the vector, and their eye tissue tolerated the dose without runaway cell division. That sounds like a low bar, but uncontrolled reprogramming has always risked tumor formation. I admit I expected safety hurdles to stall this approach in primates for another decade. Instead, early tolerance held steady. I watched the readout closely because glaucoma damage has always been treated as irreversible cell death. If resetting optic nerve cells can restore mitochondrial transport along central nervous system axons, clinical neuroprotection shifts from slowing decay to real functional recovery.